Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 617-441-5 | CAS number: 83121-18-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Genetic toxicity: in vivo
Administrative data
- Endpoint:
- in vivo mammalian somatic cell study: cytogenicity / erythrocyte micronucleus
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1983-11-21 to 1983-12-21
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- guideline study with acceptable restrictions
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 984
- Report date:
- 1984
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 474 (Mammalian Erythrocyte Micronucleus Test)
- Version / remarks:
- 26 May 1983 (first addendum)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Type of assay:
- mammalian erythrocyte micronucleus test
Test material
- Reference substance name:
- 1-(3,5-dichloro-2,4-difluorophenyl)-3-(2,6-difluorobenzoyl)urea
- EC Number:
- 617-441-5
- Cas Number:
- 83121-18-0
- Molecular formula:
- C14 H6 Cl2 F4 N2 O2
- IUPAC Name:
- 1-(3,5-dichloro-2,4-difluorophenyl)-3-(2,6-difluorobenzoyl)urea
- Test material form:
- solid: crystalline
Constituent 1
Test animals
- Species:
- mouse
- Strain:
- NMRI
- Remarks:
- KFM (outbred, SPF-quality)
- Details on species / strain selection:
- Mice are recommended for micronucleus assays as the international standard.
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Kleintierfarm Madoerin AG, 4414 Fuellinsdorf / Schwitzerland
- Age at study initiation: 7 weeks
- Weight at study initiation: 22-41 g
- Assigned to test groups randomly: Animals were randomized into the different groups after delivery using a random algorithm.
- Fasting period before study: no
- Housing: groups of 6, Makrolon Type 3, with wire mesh top
- Diet: ad libitum, pelleted standard Kliba 343-A mouse diet
- Water: ad libitum, tap water
- Acclimation period: 7 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20-24
- Humidity (%): 45-65
- Air changes (per hr): no data, air-conditioned room
- Photoperiod (hrs dark / hrs light): 12/12
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- - Vehicle used: CMC (carboxymethyl cellulose)
- Concentration of test material in vehicle: 250 mg/mL
- Amount of vehicle: 20 mL/kg bw - Details on exposure:
- PREPARATION OF DOSING SOLUTIONS: A suspension was prepared immediately before application by adding the test material to distilled water containing 2% vehicle CMC. The suspension was then homogenized. Homogeneity of the suspension was maintained during application using a magnetic stirrer. Dosing suspensions prepared immediately prior to administrationwere stable for at least 2 hours.
- Duration of treatment / exposure:
- 24, 48 and 72 hours
- Frequency of treatment:
- once
- Post exposure period:
- 24, 48, 72 hours
Doses / concentrations
- Dose / conc.:
- 5 000 mg/kg bw (total dose)
- No. of animals per sex per dose:
- 6 (only 5 animals were used for analysis)
- Control animals:
- yes, concurrent vehicle
- Positive control(s):
- Cyclophosphamide
- Justification for choice of positive control: accepted reference mutagen
- Route of administration: oral gavage
- Doses / concentrations: 50 mg/kg bw dissolved in 0.9% saline
Examinations
- Tissues and cell types examined:
- All mice were sacrificed by cervical dislocation. The femora were removed from each mouse and freed of adherent tissue. The proximal end of the femur was cut with scissors. The needle of a plastic syringe containing 0.2 mL calf serum was inserted into the proximal part of the marrow canal which was closed at the distal end. The femur was submerged in 1.5 mL calf serum in a labeled centrifuge tube. The bone marrow cells were dispersed in the calf serum as a homogeneous suspension. The tube containing the bone marrow cells of both femora was centrifuged at 1000 r.p.m. for 5 minutes. The supernatant was removed, leaving a thin layer of serum. The cells of the sediment were suspended by aspiration in a siliconized pasteur pipette.
- Details of tissue and slide preparation:
- CRITERIA FOR DOSE SELECTION: The dose applied was based on acute oral toxicity data. The acute oral LD50 study with the mice species used in this experiment indicated a LD50 value greater than 5000 mg/kg body weight (see Section 7.2.1). The dose of 5000 mg/kg body weight was used in this experiment as the expected maximum tolerated dose.
TREATMENT AND SAMPLING TIMES: At 24-, 48- and 72-hour intervals after treatment, 6 mice per sex and group were sacrificed for examination. The first 5 animals of each sex were evaluated.
DETAILS OF SLIDE PREPARATION: A small drop of the marrow serum suspension was smeared on the slide, which was identified by project code and the animal number, and allowed to dry overnight. Two slides per animal were prepared. The following day, the smears were stained using the panoptic stain method developed by Pappenheim .
METHOD OF ANALYSIS: The slides were coded before microscopic analysis. If macroscopic evaluation revealed technical imperfections, the first slide was replaced by the second slide prepared. From each animal, one thousand polychromatic erythrocytes (PCE) were scored under the microscope (magnification 1000x), for the incidence of micronuclei. Additional information could be obtained by scoring normochromatlc erythrocytes for micronuclei. The calculated ratio polychromatic to normochromatic erythrocytes (PCE/NCE), based on 1000 erythrocytes scored per slide, measured the toxic efficacy of the test material.
- Evaluation criteria:
- The frequencies of micronuclei of the treated male and female groups were compared with those of the negative control groups at each sampling time. A regression model assuming a Poisson distribution was applied. Estimation and testing were performed by maximum likelihood method. A test material which produced no statistically significant and reproducible positive response at any one of the test points is considered non-mutagenic in this system.
- Statistics:
- Poisson heterogenicity test, Maximum Likelihood Method
Results and discussion
Test results
- Key result
- Sex:
- male/female
- Genotoxicity:
- negative
- Toxicity:
- no effects
- Vehicle controls validity:
- valid
- Negative controls validity:
- not applicable
- Positive controls validity:
- valid
- Additional information on results:
- RESULTS OF DEFINITIVE STUDY
After a single application of the test material at 5000 mg/kg body weight by gavage, no significant substance-related increase of micronucleated polychromatic erythrocytes was observed in either male and female treated groups when compared with corresponding negative control groups. These results were found in the three examination times, 24, 48 and 72 hours post-application, respectively. No evidence of toxic effects of the test material was observed. The positive control groups receiving cyclophosphamide exhibited a significant and clear increase in the number of micronucleated polychromatic erythrocytes and thus validated the test. The dose used for this reference mutagen exhibited a toxic effect as shown by the reduced PCE/NCE ratio.
- Appropriateness of dose levels and route: No treatment-related symptoms and no death occurred during the application period in this study. From ADME studies in rodents (see section 7.1) systemic exposure after oral gavage was reported, however absorption of the substance in rodents was reported to be low and independent of the dose level and sex. Following administration of a single high dose of 750 mg/kg bw in male rats nearly constant plasma levels were reached during the first 8 hours post treatment (1.17 -1.72 µg/mL). A peak mean concentration of 3.27 µg/mL occurred at 24 hour in males. In females, the corresponding values were 0.98 -1.43 µg/mL. From the 2nd day post-treatment, the plasma levels declined to reach 0.06 and 0.08 µg/mL after 7 days in males and females respectively. From all available ADME studies an absorption rate of <10% of the dose can be estimated. However, exposure of the target tissue in this in vivo micronucleus test is expected at least for the 24 h time point. In an acute oral toxicity study in which the same mouse stain and batch of the test item have been used the LD50 was > 5000 mg/kg bw and dyspnea and ruffled fur were observed in all mice as clinical symptoms indicating systemic exposure (see section 7.2).
- Statistical evaluation: There was no statistical evidence for differences between the negative control groups and the corresponding treatment groups.
Any other information on results incl. tables
Mean micronuclei scored at different time points following treatment with the test substance:
Test group | 24 hours post-application | 48 hours post-application | 72 hours post-application | ||||||
N | Mean # micronuclei ± SD | Mean Ratio PCE/NCE | N | Mean # micronuclei ± SD | Mean Ratio PCE/NCE | N | Mean # micronuclei ± SD | Mean Ratio PCE/NCE | |
Vehicle control (2% CMC) | 10 | 1.1 ± 0.74 | 1.47 | 10 | 0.3 ± 0.48 | 1.46 | 10 | 0.6 ± 0.70 | 1.41 |
Test group (5000 mg/kg bw tet substance) | 10 | 1.5 ± 0.97 | 1.73 | 10 | 1.1 ± 0.88 | 1.54 | 10 | 0.8 ± 0.92 | 1.50 |
Positive control (50 mg/kg bw CPA) | 10 | 32.9 ± 5.99 | 1.02 | 10 | 20.9 ± 4.90 | 0.74 | 10 | 7.7 ± 1.42 | 0.50 |
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.